Seagen Biotech company asked two metastatic breast cancer (MBC) advocates Eva Schumacher from Mamma Mia online German cancer magazine and patient living with MBC and myself Jo Taylor founder of
Sandy Sexton, patient advocate for METUPUK, is campaigning in Scotland on behalf of secondary/metastatic Breast Cancer patients. In October last year, after 18 months of debilitating back pain, Sandy was
Tassia Haines – METUPUK (Wales) member, patient advocate & fantastic artist. Back in February, I had to go into hospital after side effects from being on Trodelvy. I wanted
At METUPUK, we campaign for new and better therapies for patients with secondary breast cancer. One of our recent campaigns, #TrodelvyNow helped to make a new type of drug, Trodelvy (sacituzumab govitecan) available for SBC patients in the UK. Scientist and METUPUK volunteer, Helen, explains how Trodelvy works and why it’s important that more drugs like this get to patients urgently.
‘The Darker Side of Pink’ was launched in Breast Cancer Awareness Month 2021 by METUPUK – the UK’s only patient advocacy group dedicated to Metastatic (Secondary) Breast Cancer (MBC) –
If a person has a heart attack, do they get told that they will never have a heart attack again and they are free of heart disease?
METUPUK was over the moon to receive an amazing donation from Hearts & Hope 4 Helen. The cheque was handed over to METUPUK at the Darker Pink exhibition, which is currently in the Michell Library in Glasgow.
METUPUK welcomes the Scottish Medicines Consortium (SMC) decision to accept pembrolizumab (Keytruda, Merck Sharp and Dohme) plus chemotherapy (paclitaxel or nab-paclitaxel) for use on the NHS in Scotland. Pembrolizumab is
Today we want to honour our friend and MetUpUK member Emma Hillier.
A diagnosis of cancer is a major life event. None of us is immune to the
potential of developing the disease. It doesn’t discriminate by age, gender,
sexual orientation or ethnicity. It can also develop in any part of the body. In
the case of breast cancer, one in seven women will be diagnosed with it
during their lifetime. Approximately 30% of those women will go on to develop secondary breast cancer.